Probiotics \textit{C} the Difference for the Prevention of \textit{C} \textit{diff}

Clinical Question: Do probiotics prevent \textit{Clostridium difficile}-associated diarrhea (CDAD) in patients taking antibiotics?

Bottom Line: Probiotics may reduce the incidence of CDAD in patients on antibiotics, preventing one case of CDAD in 29 but no benefits are seen in studies not funded by manufacturers. Furthermore, the ideal product, length of therapy, and safety of probiotics (particularly in the immunocompromised) is unknown.

Evidence:
- Cochrane review\textsuperscript{1} of 31 Randomized Controlled Trials (RCTs) of 4492 mostly adult inpatients using a variety of probiotics for a variable length of time (majority for duration of antibiotic use or up to 14 days after antibiotics finished):
  - Outcomes:
    - Reduction in CDAD incidence:
      - Probiotics 2.0\%, placebo 5.5\%, number needed to treat (NNT)=29.
  - Limitations:
    - 13 trials missed up to 45\% of CDAD data.
    - Eight trials did not report CDAD.
    - Most studies funded by probiotic manufacturer.
- Similar results found in older systematic reviews.\textsuperscript{2-4}
- RCT\textsuperscript{5} of 2981 elderly inpatients given probiotic (containing \textit{L acidophilus} and \textit{Bifidobacterium}) or placebo for 21 days.
  - No difference in CDAD (probiotic 1.2\%, placebo 0.8\%), but event rate lower than in other studies.
  - Systematic review\textsuperscript{6} including this study found similar results to Cochrane review.
- With the above RCT\textsuperscript{5} the Cochrane meta-analysis\textsuperscript{1} was re-run examining the influence of funding,\textsuperscript{7} the relative risk (confidence intervals) of CDAD was:
  - 0.79 (0.41-1.53) in public funded, no effect.
0.34 (0.24-0.48) in industry funded, reduced CDAD with probiotics.

**Context:**
- **Risk factors for CDAD:**
  - Primarily: antibiotic use (especially cephalosporins, clindamycin and quinolones) and hospitalization.
  - Also: Advancing age, concurrent diseases (especially inflammatory bowel disease), use of corticosteroids, PPIs and H2RAs.
- Probiotics also decrease antibiotic-associated diarrhea in adults and children (NNT=13).
- Cases of fungemia and bacteremia reported in immunocompromised patients given probiotic, but overall adverse events seem similar to placebo.
- American guidelines do not endorse probiotics for CDAD prevention, but they do not cite systematic reviews discussed here.
- The Canadian Pediatrics Society provide conflicting recommendations regarding probiotics for CDAD prevention.
- Approximate Canadian cost for 14 days of probiotics with evidence for CDAD prevention:
  - Bio-K+ (*L acidophilus, L casei*): $13
  - TuZen (*L plantarum* 299v): $37
  - Florastor (*S boulardii*): $45
  - VSL#3 (8 species): $112

**Original Authors:** Daniel Rainkie BScPharm ACPR PharmD, Michael R Kolber MD CCFP MSc

**Updated:** Ricky Turgeon BSc(Pharm) ACPR PharmD

**Reviewed:** G Michael Allan MD CCFP

**References:**

Tools for Practice is a biweekly article summarizing medical evidence with a focus on topical issues and practice modifying information. It is coordinated by G. Michael Allan, MD, CCFP and the content is written by practising family physicians who are joined occasionally by a health professional from another medical specialty or health discipline. If you are not a member of the ACFP and would like to receive the TFP emails, please contact subscribetfp@acfp.ca to be added to the distribution list. Archived articles are available on the ACFP website.

This communication reflects the opinion of the authors and does not necessarily mirror the perspective and policy of the Alberta College of Family Physicians.